Ritu Bhatt

Ritu Bhatt investigates GLP-1 receptor agonists (semaglutide, liraglutide) as treatments for NASH that could reduce HCC risk by reversing liver inflammation and fibrosis. Her research has characterized the hepatic effects of GLP-1 agonists beyond glycemic control, including anti-inflammatory, anti-fibrotic, and anti-apoptotic actions in hepatocytes. She is evaluating whether GLP-1 agonist-mediated NASH resolution translates into measurable reduction in HCC incidence in long-term clinical studies. Her work bridges endocrinology, hepatology, and cancer prevention.